Lead Product(s): GlymaxX
Therapeutic Area: Oncology
Highest Development Status: Undisclosed Product Type: Large molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 08, 2020
ProBioGen AG, has signed a commercial license agreement with Roche for applying ProBioGenâ€™s proprietary GlymaxXÂ® technology to boost the antibodyâ€™s ADCC anti-tumor activity.